These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7302920)

  • 1. Comparative plasma heparin levels after subcutaneous administration of calcium and magnesium heparin.
    Follea G; Trzeciak MC; Dechavanne M
    Thromb Res; 1981 Jul 1-15; 23(1-2):33-9. PubMed ID: 7302920
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative plasma heparin levels after subcutaneous sodium and calcium heparin.
    Low J; Biggs JC
    Thromb Haemost; 1978 Oct; 40(2):397-406. PubMed ID: 734636
    [No Abstract]   [Full Text] [Related]  

  • 3. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
    Sandler RM; Liebman HA; Patch MJ; Teitelbaum A; Levine AM; Feinstein DI
    Cancer; 1982 Nov; 50(10):2106-10. PubMed ID: 6957257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent subcutaneous injection of calcium heparin for anticoagulant control.
    Suzuki M; Edis B; Sloman G
    Med J Aust; 1971 Jul; 2(2):96-100. PubMed ID: 5094800
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin.
    Gerhards H; Eberhardt C
    Am J Vet Res; 1988 Jan; 49(1):13-8. PubMed ID: 3354959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma.
    Greenberg CS; Adams JP; Mullen PE; Koepke JA
    Am J Clin Pathol; 1986 Oct; 86(4):484-9. PubMed ID: 3766461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma.
    Dahlman TC; Hellgren MS; Blombäck M
    Am J Obstet Gynecol; 1989 Aug; 161(2):420-5. PubMed ID: 2764060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of heparin fractions: some overlooked considerations.
    Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):227-36. PubMed ID: 3898374
    [No Abstract]   [Full Text] [Related]  

  • 10. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 11. Automated instrumentation and the laboratory diagnosis of bleeding and thrombotic disorders.
    Walenga J; Fareed J; Bermes EW
    Semin Thromb Hemost; 1983 Jul; 9(3):172-93. PubMed ID: 6351253
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously.
    Bergqvist D; Hedner U; Sjörin E; Holmer E
    Thromb Res; 1983 Nov; 32(4):381-91. PubMed ID: 6658720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heparin level and coagulation potential after subcutaneous injection of 7500 international units of heparin calcium].
    Briel RC
    Dtsch Med Wochenschr; 1984 Jun; 109(25):993-6. PubMed ID: 6734457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
    Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
    Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay.
    Dawes J; Prowse CV; Pepper DS
    Thromb Res; 1986 Dec; 44(5):683-93. PubMed ID: 2433788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of heparin after a single intravenous or subcutaneous injection].
    Mombelli G; Schaedelin J; Beck EA
    Schweiz Med Wochenschr; 1977 Jun; 107(23):810-5. PubMed ID: 877532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma.
    Schmidt M; Barrowcliffe TW; Gray E; Watton J; Harenberg J
    Thromb Res; 1991 Sep; 63(5):503-8. PubMed ID: 1755003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
    Sandler RM; Liebman HA; Patch MJ; Teitelbaum A; Levine AM; Feinstein DI
    Cancer; 1983 Feb; 51(4):681-5. PubMed ID: 6571800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.